Registry for long-term treatment outcomes of psoriasis and psoriatic arthritis in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PsoBest registry collects data on the long-term treatment outcomes of patients with moderate to severe psoriasis and psoriatic arthritis in Germany. It documents the effectiveness, safety, and patient-reported outcomes of systemic therapies, including both conventional and biologic treatments. The registry aims to evaluate the long-term course of treatment for approximately 3,500 patients, focusing on real-world effectiveness and optimal maintenance dosages. By analyzing this data, the registry seeks to provide insights into treatment benefits, side effects, and predictors of response over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist
* age ≥ 18 years
* being administered a specific systemic drug for the first time
* informed consent to participate
* sufficient language skills (German)

Exclusion criteria:

* lack of informed consent
* patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)

Where it's running

• Nationwide group of dermatological centers, hospitals and medical offices
  Hamburg, Germany Recruiting

Study contacts

• Principal investigator: Matthias Augustin, Prof. Dr. — Universitätsklinikum Hamburg-Eppendorf

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRAF3IP2 gene variation (rs13190932) in people with psoriasis and psoriatic arthritis

  This trial will test whether the TRAF3IP2 (rs13190932) gene variant changes how adults with psoriasis or psoriatic arthritis respond to methotrexate treatment.

  Recruiting South Valley University · Qina · NCT07086924

• Observational study on psoriasis and its risk for arthritis

  This study is trying to find out which adults with psoriasis are more likely to develop psoriatic arthritis so that steps can be taken to prevent it.

  Recruiting University of Oxford · Oxford, Oxfordshire · NCT05858528

• Examining cytokine levels in psoriasis and psoriatic arthritis patients

  This study is trying to see how certain proteins in the blood and skin of people with psoriasis and psoriatic arthritis can help us understand these conditions better.

  Recruiting Poitiers University Hospital · Poitiers · NCT05307809

• Educational tool for melanoma patients with autoimmune diseases

  This study is testing a new educational tool to help melanoma patients with autoimmune diseases understand their treatment options better and see how easy it is for them to use.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04751396

• Understanding chronic inflammatory systemic diseases and their treatments

  This study looks at patients with chronic inflammatory diseases to see how these conditions are related and how they can be treated better.

  Recruiting Centre Hospitalier Universitaire de Besancon · Besançon · NCT04191395

• Using nivolumab to treat patients with autoimmune disorders and advanced cancer

  This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.

  Recruiting at 40 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 51 other locations · NCT03816345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.